| IPO Company Profile |
| SEC Filings | Peer IPO Companies |
| Centaur Pharmaceuticals, Inc. |
| 484 Oakmead Parkway, Sunnyvale, CA 94086 * (408) 822-1600 |
| The company is developing a novel class of small molecule pharmaceutical compunds, which the company calls NRTs (nitrone related therapeutics), for the treatment of diseases involving oxidative stress. |
| Manager | Tier | Phone |
| Vontobel Securities Ltd. | Lead Manager | |
| Vector Securities International, Inc. | Co-manager | (800) 546-1231 |
| NASNTL: | CEN | Manufacturing: | SIC 2384 | |
| Type of Shares: | Common Shares | Filing Date: | 6/18/98 | |
| U.S. Shares Filed: | 5,600,000 | Filing Range: | $13.00 - $15.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $78,400,000 | |
| Primary Shares: | 4,900,000 | Expenses: | - | |
| Secondary Shares: | 700,000 | Post-IPO Shares: | ||
| Employees: | 90 |
| Issuer's Law Firm: | Fenwick & West |
| Bank's Law Firm: | Shearman & Sterling |
| Auditor: | Ernst & Young |
Dollar amounts in U.S. millions except for per share data | |||||
| 3 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Audited Income | Balance Sheet | ||
| 12/31/97 | 3/31/98 | 3/31/97 | 3/31/98 | ||
| Revenue: | $11.77 | $2.94 | $3.57 | Assets: | $22.97 |
| Net Income: | -$4.73 | -$1.03 | -$0.18 | Curr Assets: | $11.74 |
| EPS: | -$0.36 | -$0.07 | Liabilities: | $3.95 | |
| Prior EPS: | Curr Liab: | $2.09 | |||
| Cash Flow/Oper: | -$6.17 | -$1.51 | $0.02 | Equity: | $19.02 |
| Cash Flow/Fin: | $16.38 | $0.00 | $8.90 | Cash: | $10.67 |
| Cash Flow/Inv: | -$14.44 | $4.14 | -$10.51 | Working Cap: | $9.66 |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for funding of research and development, capital expenditures and general corporate purposes including working capital. |